Covidien launches next-generation stent in Europe
This article was originally published in Clinica
Executive Summary
Covidien has launched its EverFlex+ self-expanding peripheral stent in Europe. The device is a next-generation version of the EverFlex stent, originally developed by ev3, which was launched worldwide in 2006 for peripheral arterial disease and stenting of the superficial femoral artery. Covidien agreed to buy ev3 in June (www.clinica.co.uk, 2 June 2010), and the purchase was completed in July. EverFlex+, which was CE marked in October 2010, has been designed to lower the risk of fracture when elongated, thereby improving clinical outcomes. It has similar radial strength and flexibility as the older device, but greater durability, Dublin, Ireland-based Covidien claims. EverFlex+ is not currently available in the US.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.